Bob McDowell
Co-founder & Scientific AdvisorDr. Bob McDowell, Ph.D., is Co-founder & Scientific Advisor of Kardigan, Inc. He has extensive scientific experience and brings decades of successful leadership in biopharmaceutical drug discovery to Kardigan. An accomplished scientist, he has expertise in small molecule drug discovery in cardiovascular disease, inflammation and oncology, with multiple compounds advancing into clinical trials and beyond. He was a key member of the team that founded cardiovascular health company MyoKardia in 2012, where he advanced treatment breakthroughs as senior vice president of Drug Discovery and chief scientific officer until the company was acquired by Bristol Myers Squibb (BMS) in 2020. After the acquisition, he served as vice president of Research at BMS where he facilitated the MyoKardia team’s integration into the larger firm. His considerable leadership experience includes roles at 3-V Biosciences, where his direction led to program advancements; Sunesis Pharmaceuticals, where he oversaw drug discovery, translational research and manufacturing functions; and Axys Pharmaceuticals, where he led the structural chemistry group. Before joining Axys, he was a senior scientist at Genentech, where he developed successful strategies for peptidomimetic design. He has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents. He holds a B.S. in Chemistry and Physics from Butler University and a Ph.D. in Chemistry from the University of California at Berkeley.
Positions
- Company NameKardigan, Inc.Stock CodeKARDPositionCo-founder & Scientific AdvisorColleagues
- TATassos Anastasios E. GianakakosCo-Founder, President, CEO & Chairman
- JEJay EdelbergCo-founder & Chief Medical Officer
- BPBrianne PuglisiChief Financial Officer
- LALeslie A. LeinwandCo-Founder
- KJKimberly Johnston PopovitsIndependent Director
- DPDavid P. MeekerIndependent Director
- KRKristin ReinkeIndependent Director
- PLPaul L. BernsIndependent Director
